Dsm IP Assets B.v.

Szabolcs Peter

Joseph Schwager

Jaroslav A Kralovec

Hasan Mohajeri

Bernd Mussler

Weerasinghe M Indrasena

Lisette De Groot

Stephanie J M Krammer-Lukas

Jonas Witter-Schegg

Elske Maria Brouwer-Brolsma

Edith Johanna Maria Feskens

Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver&#x2014;known as non-alcoholic fatty liver disease (NAFLD)&#x2014;and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.

Treatment for non-alcoholic fatty liver diseases

The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver&#x2014;known as non-alcoholic fatty liver disease (NAFLD)&#x2014;and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 may be administered in combination with Vitamin D or other ingredients.

Use of 25-hydroxyvitamin D3 to enhance executive functions

Growing community of inventors

Kaiseraugst, Switzerland

Szabolcs Peter